Home › Funds › Opaleye Management Inc. › RYTM
Opaleye Management Inc. position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
Opaleye Management Inc. reported holding 122,500 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$13.6M, representing 1.23% of its reported portfolio and ranking #23 among its reported holdings. Opaleye Management Inc. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s RYTM position evolved
Opaleye Management Inc. first disclosed a stake in RYTM in Q3 2023 at 653,000 shares (US$15.0M). The position peaked in Q3 2025 at 461,700 shares, worth US$46.6M. Across 12 filings, Opaleye Management Inc. increased the stake 0 time(s), trimmed it 8 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 122,500 shares valued at US$13.6M. Notable position changes include a 29% trim in Q4 2025 (shares fell 19% over the following quarter), a 63% trim in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 653.00K | $14.97M | New |
| Q4 2023 | 610.00K | $28.04M | Reduce |
| Q1 2024 | 515.00K | $22.31M | Reduce |
| Q2 2024 | 515.00K | $21.15M | Hold |
| Q3 2024 | 500.00K | $26.20M | Reduce |
| Q4 2024 | 500.00K | $27.99M | Hold |
| Q1 2025 | 490.00K | $25.96M | Reduce |
| Q2 2025 | 475.00K | $30.02M | Reduce |
| Q3 2025 | 461.70K | $46.63M | Reduce |
| Q4 2025 | 330.00K | $35.32M | Reduce |
| Q1 2026 | 123.00K | $35.32M | Reduce |
| Q2 2026 | 122.50K | $13.60M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 52 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.21M sh · $245.22M · Q2 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Siren, L.L.C. 1.14M sh · $126.16M · Q2 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
- BRAIDWELL LP 381.13K sh · $42.32M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held RYTM?
Opaleye Management Inc. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Opaleye Management Inc.'s current position in RYTM?
As of Q2 2026, Opaleye Management Inc. holds 122.50K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $13.60M, representing 1.23% of its reported portfolio and ranking #23.
Has Opaleye Management Inc. been buying or selling RYTM?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. held unchanged its position in RYTM. The position peaked in Q3 2025 at 461.70K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.